Nykode Therapeutics
Nykode Therapeutics ASA is a Norwegian clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies. The company utilizes its proprietary Vaccibody technology platform to engineer targeted therapeutic vaccines for cancer indications and infectious diseases. Revenue is primarily generated through research partnerships, licensing deals, and milestone payments from international pharmaceutical collaborators. Its end markets encompass oncology and infectious disease treatment sectors within global healthcare. Nykode Therapeutics maintains a prominent position within the Nordic biotechnology sector due to its innovative modular vaccine technology platform. The company is headquartered in Oslo, Norway, and its shares are listed on the Oslo Børs stock exchange.
6 of the funds FundTelligence covers report a position in Nykode Therapeutics.
- Legal name
- NYKODE THERAPEUTICS ASA
- Sector
- Health Care
- Country
- Norway
- Funds holding it
- 6
Funds holding Nykode Therapeutics
- Danske Invest Norge Vekst — Danske Invest · 1.8 % (full portfolio disclosed, September 2026)
- Storebrand Indeks Norge — Storebrand · 0.04 % (full portfolio disclosed, October 2026)
- DNB Norge Indeks — DNB · 0.04 % (full portfolio disclosed, September 2026)
- KLP AksjeNorge Indeks — KLP · 0.03 % (full portfolio disclosed, June 2026)
- Danske Invest Norway Index Restricted — Danske Invest · 0.03 % (full portfolio disclosed, September 2026)
- Handelsbanken Norden Index Criteria — Handelsbanken · 0.03 % (full portfolio disclosed, October 2026)